Circulate Health is excited to announce that we have successfully raised $12,000,000 in our latest funding round, marking a pivotal moment in our mission to reverse aging and improve overall health outcomes. As pioneers in developing cutting-edge technologies and treatments, our company is deeply rooted in rigorous scientific research and evidence-based clinical practices. The substantial capital infusion will bolster the continued advancement of our Therapeutic Plasma Exchange (TPE) program—a treatment that has quickly become our patented flagship product. TPE works by safely removing toxic, inflammatory, disease-causing, and age-accelerating substances from the bloodstream, and its promising results are already improving lives today.
This funding will enable us to expand our robust research initiatives, further refine our TPE treatment protocols, and accelerate the pace of our clinical trials. By deepening our scientific investigations and enhancing our technology platform, we aim to broaden the impact of our therapies to benefit a larger patient population. In addition to strengthening our laboratory and clinical capabilities, the funds will support collaborations with top-tier research institutions and experts in the field of anti-aging medicine. This strategic investment is not only a vote of confidence in our innovative approach but also a commitment to a healthier, longer future. At Circulate Health, we remain devoted to pioneering breakthroughs that redefine how individuals age, ensuring that our dedication to integrity, scientific rigor, and patient-centered care continues to transform lives for the better.
